Non-B HIV-1 subtypes in sub-Saharan Africa: impact of subtype on protease inhibitor efficacy

References

Abecasis, A.B., Deforche, K., Snoeck, J., Bacheler, L.T., McKenna, P., Carvalho, A.P., Gomes, P., Camacho, R.J., and Vandamme, A.M. (2005). Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19, 1799–1806.Search in Google Scholar

Ahmed, S.M., Kruger, H.G., Govender, T., Maguire, G.E.M., Sayed, Y., Ibrahim, M.A.A., Naicker, P., and Soliman, M.E.S. (2013). Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR. Chem. Biol. Drug Des. 81, 208–218.Search in Google Scholar

Alaeus, A., Lidman, K., Bjorkman, A., Giesecke, J., and Albert, J. (1999). Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A–D. AIDS 13, 901–907.Search in Google Scholar

Alexander, C.S., Montessori, V., Wynhoven, B., Dong, W., Chan, K., O’Shaughnessy, M.V., Mo, T., Piaseczny, M., Montaner, J.S., and Harrigan, P.R. (2002). Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir. Ther. 7, 31–35.Search in Google Scholar

Babe, L.M., Rose, J., and Craik, C.S. (1992). Synthetic “interface” peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci. 1, 1244–1253.Search in Google Scholar

Barth, R.E., van der Loeff, M.F., Schuurman, R., Hoepelman, A.I., and Wensing, A.M. (2010). Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect. Dis. 10, 155–166.Search in Google Scholar

Bessong, P.O. (2008). Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors. Trop. Med. Int. Health 13, 144–151.Search in Google Scholar

Bessong, P.O., Mphahlele, J., Choge, I.A., Obi, L.C., Morris, L., Hammarskjold, M.L., and Rekosh, D.M. (2006). Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res. Hum. Retroviruses 22, 1306–1312.Search in Google Scholar

Cane, P.A., de Ruiter, A., Rice, P., Wiselka, M., Fox, R., and Pillay, D. (2001). Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39, 2652–2654.Search in Google Scholar

Choudhury, S., Everitt, L., Pettit, S.C., and Kaplan, A.H. (2003). Mutagenesis of the dimer interface residues of tethered and untethered HIV-1 protease result in differential activity and suggest multiple mechanisms of compensation. Virology 307, 204–212.Search in Google Scholar

Coetzee, D., Hildebrand, K., Boulle, A., Maartens, G., Louis, F., Labatala, V., Reuter, H., Ntwana, N., and Goemaere, E. (2004). Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887–895.Search in Google Scholar

de Oliveira, T., Engelbrecht, S., Janse van Rensburg, E., Gordon, M., Bishop, K., zur Megede, J., Barnett, S.W., and Cassol, S. (2003). Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J. Virol. 77, 9422–9430.Search in Google Scholar

Del Amo, J., Petruckevitch, A., Phillips, A., Johnson, A.M., Stephenson, J., Desmond, N., Hanscheid, T., Low, N., Newell, A., Obasi, A., et al. (1998). Disease progression and survival in HIV-1-infected Africans in London. AIDS 12, 1203–1209.Search in Google Scholar

Delgado, E., Ampofo, W.K., Sierra, M., Torpey, K., Perez-Alvarez, L., Bonney, E.Y., Mukadi, Y.D., Lartey, M., Nyarko, C., Amenyah, R.N., et al. (2008). High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study. J. Acquir. Immune. Defic. Syndr. 48, 599–606.Search in Google Scholar

Descamps, D., Chaix, M.L., Andre, P., Brodard, V., Cottalorda, J., Deveau, C., Harzic, M., Ingrand, D., Izopet, J., Kohli, E., et al. (2005). French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001–2002. J. Acquir. Immune. Defic. Syndr. 38, 545–552.Search in Google Scholar

Foster, G.M., Ambrose, J.C., Hue, S., Delpech, V.C., Fearnhill, E., Abecasis, A.B., Leigh Brown, A.J., and Geretti, A.M. (2014). Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of circulating recombinant form (CRF) 50_A1D. PLoS One 9, e83337.Search in Google Scholar

Hansen, J., Billich, S., Schulze, T., Sukrow, S., and Moelling, K. (1988). Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. EMBO J. 7, 1785–1791.Search in Google Scholar

Harrigan, P.R., Hertogs, K., Verbiest, W., Pauwels, R., Larder, B., Kemp, S., Bloor, S., Yip, B., Hogg, R., Alexander, C., et al. (1999). Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 13, 1863–1871.Search in Google Scholar

Haynes, B.F. and Montefiori, D.C. (2006). Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347–363.Search in Google Scholar

Hemelaar, J. (2012). The origin and diversity of the HIV-1 pandemic. Trends. Mol. Med. 18, 182–192.Search in Google Scholar

Hemelaar, J., Gouws, E., Ghys, P.D., and Osmanov, S. (2011). Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 25, 679–689.Search in Google Scholar

Holguin, A., de Mulder, M., Yebra, G., Lopez, M., and Soriano, V. (2008). Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr. HIV Res. 6, 327–334.Search in Google Scholar

Hu, S.L. and Stamatatos, L. (2007). Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5, 507–513.Search in Google Scholar

Huang, L. and Chen, C. (2010). Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells. AIDS Res. Ther. 7, 27.Search in Google Scholar

Ito, F.M., Petroni, J.M., de Lima, D.P., Beatriz, A., Marques, M.R., de Moraes, M.O., Costa-Lotufo, L.V., Montenegro, R.C., Magalhaes, H.I., and Pessoa Cdo, O. (2007). Synthesis and biological evaluation of rigid polycyclic derivatives of the diels-alder adduct tricyclo[6.2.1.02,7]undeca-4,9-dien-3,6-dione. Molecules 12, 271–282.Search in Google Scholar

Kanizsai, S., Ghidan, A., Ujhelyi, E., Banhegyi, D., and Nagy, K. (2010). Monitoring of drug resistance in therapy-naive HIV infected patients and detection of African HIV subtypes in Hungary. Acta Microbiol. Immunol. Hung. 57, 55–68.Search in Google Scholar

Kantor, R. and Katzenstein, D. (2003). Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 5, 25–35.Search in Google Scholar

Kaplan, A.H., Zack, J.A., Knigge, M., Paul, D.A., Kempf, D.J., Norbeck, D.W., and Swanstrom, R. (1993). Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67, 4050–4055.Search in Google Scholar

Karpoormath, R., Sayed, Y., Govender, T., Kruger, H.G., Soliman, M.E.S., and Maguire, G.E.M. (2013). Novel PCU cage diol peptides as potential targets against wild-type CSA HIV-1 protease: synthesis, biological screening and molecular modelling studies. Med. Chem. Res. 22, 3918–3933.Search in Google Scholar

Kozisek, M., Saskova, K.G., Rezacova, P., Brynda, J., van Maarseveen, N.M., De Jong, D., Boucher, C.A., Kagan, R.M., Nijhuis, M., and Konvalinka, J. (2008). Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J. Virol. 82, 5869–5878.Search in Google Scholar

Makatini, M.M., Petzold, K., Sriharsha, S.N., Ndlovu, N., Soliman, M.E., Honarparvar, B., Parboosing, R., Naidoo, A., Arvidsson, P.I., Sayed, Y., et al. (2011). Synthesis and structural studies of pentacycloundecane-based HIV-1 PR inhibitors: a hybrid 2D NMR and docking/QM/MM/MD approach. Eur. J. Med. Chem. 46, 3976–3985.Search in Google Scholar

Makatini, M.M., Petzold, K., Alves, C.N., Arvidsson, P.I., Honarparvar, B., Govender, P., Govender, T., Kruger, H.G., Sayed, Y., Lameira, J., et al. (2013). Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors. J. Enzyme Inhib. Med. Chem. 28, 78–88.Search in Google Scholar

Martinez-Cajas, J.L., Pai, N.P., Klein, M.B., and Wainberg, M.A. (2009). Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008). J. Int. AIDS Soc. 12, 11.Search in Google Scholar

Mendoza, Y., Bello, G., Castillo Mewa, J., Martinez, A.A., Gonzalez, C., Garcia-Morales, C., Avila-Rios, S., Reyes-Teran, G., and Pascale, J.M. (2014). Molecular epidemiology of HIV-1 in Panama: origin of non-B subtypes in samples collected from 2007 to 2013. PLoS One 9, e85153.Search in Google Scholar

Moore, P.L., Gray, E.S., Wibmer, C.K., Bhiman, J.N., Nonyane, M., Sheward, D.J., Hermanus, T., Bajimaya, S., Tumba, N.L., Abrahams, M.R., et al. (2012). Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688–1692.Search in Google Scholar

Mosebi, S., Morris, L., Dirr, H.W., and Sayed, Y. (2008). Active-site mutations in the South African human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study. J. Virol. 82, 11476–11479.Search in Google Scholar

Naicker, P., Achilonu, I., Fanucchi, S., Fernandes, M., Ibrahim, M.A.A., Dirr, H.W., Soliman, M.E.S., and Sayed, Y. (2013a). Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance. J. Biomol. Struct. Dyn. 31, 1370–1380.Search in Google Scholar

Naicker, P., Seele, P., Dirr, H.W., and Sayed, Y. (2013b). F99 is critical for dimerization and activation of South African HIV-1 subtype C protease. Protein J. 32, 560–567.Search in Google Scholar

Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S., and Boucher, C.A. (1999). Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13, 2349–2359.Search in Google Scholar

Olomola, T.O., Klein, R., Mautsa, N., Sayed, Y., and Kaye, P.T. (2013). Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors. Bioorg. Med. Chem. 21, 1964–1971.Search in Google Scholar

Pawar, S.A., Jabgunde, A.M., Maguire, G.E., Kruger, H.G., Sayed, Y., Soliman, M.E., Dhavale, D.D., and Govender, T. (2013). Linear and cyclic glycopeptide as HIV protease inhibitors. Eur. J. Med. Chem. 60, 144–154.Search in Google Scholar

Pereira-Vaz, J., Duque, V., Trindade, L., Saraiva-da-Cunha, J., and Melico-Silvestre, A. (2009). Detection of the protease codon 35 amino acid insertion in sequences from treatment-naive HIV-1 subtype C infected individuals in the Central Region of Portugal. J. Clin. Virol. 46, 169–172.Search in Google Scholar

Perno, C.F., Cozzi-Lepri, A., Forbici, F., Bertoli, A., Violin, M., Stella Mura, M., Cadeo, G., Orani, A., Chirianni, A., De Stefano, C., et al. (2004). Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J. Infect. Dis. 189, 1983–1987.Search in Google Scholar

Pettit, S.C., Gulnik, S., Everitt, L., and Kaplan, A.H. (2003). The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J. Virol. 77, 366–374.Search in Google Scholar

Pettit, S.C., Clemente, J.C., Jeung, J.A., Dunn, B.M., and Kaplan, A.H. (2005). Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J. Virol. 79, 10601–10607.Search in Google Scholar

Pillay, D., Walker, A.S., Gibb, D.M., de Rossi, A., Kaye, S., Ait-Khaled, M., Munoz-Fernandez, M., and Babiker, A. (2002). Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect. Dis. 186, 617–625.Search in Google Scholar

Plantier, J.C., Leoz, M., Dickerson, J.E., De Oliveira, F., Cordonnier, F., Lemee, V., Damond, F., Robertson, D.L., and Simon, F. (2009). A new human immunodeficiency virus derived from gorillas. Nat. Med. 15, 871–872.Search in Google Scholar

Rhee, S.Y., Taylor, J., Wadhera, G., Ben-Hur, A., Brutlag, D.L., and Shafer, R.W. (2006). Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103, 17355–17360.Search in Google Scholar

Robertson, D.L., Anderson, J.P., Bradac, J.A., Carr, J.K., Foley, B., Funkhouser, R.K., Gao, F., Hahn, B.H., Kalish, M.L., Kuiken, C., et al. (2000). HIV-1 nomenclature proposal. Science 288, 55–56.Search in Google Scholar

Rose, R.E., Gong, Y.F., Greytok, J.A., Bechtold, C.M., Terry, B.J., Robinson, B.S., Alam, M., Colonno, R.J., and Lin, P.F. (1996). Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93, 1648–1653.Search in Google Scholar

Rose, R.B., Craik, C.S., and Stroud, R.M. (1998). Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37, 2607–2621.Search in Google Scholar

Rousseau, C.M., Learn, G.H., Bhattacharya, T., Nickle, D.C., Heckerman, D., Chetty, S., Brander, C., Goulder, P.J., Walker, B.D., Kiepiela, P., et al. (2007). Extensive intrasubtype recombination in South African human immunodeficiency virus type 1 subtype C infections. J. Virol. 81, 4492–4500.Search in Google Scholar

Shafer, R.W. and Schapiro, J.M. (2008). HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10, 67–84.Search in Google Scholar

Shafer, R.W., Chuang, T.K., Hsu, P., White, C.B., and Katzenstein, D.A. (1999). Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res. Hum. Retroviruses 15, 65–69.Search in Google Scholar

Stamatatos, L., Morris, L., Burton, D.R., and Mascola, J.R. (2009). Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15, 866–870.Search in Google Scholar

Taylor, B.S., Sobieszczyk, M.E., McCutchan, F.E., and Hammer, S.M. (2008). The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358, 1590–1602.Search in Google Scholar

The Joint Nations Program on HIV/AIDS (UNAIDS) (2013). Global report: UNAIDS report on the global AIDS epidemic 2013 (Geneva, Switzerland: UNAIDS).Search in Google Scholar

Tomaras, G.D., Binley, J.M., Gray, E.S., Crooks, E.T., Osawa, K., Moore, P.L., Tumba, N., Tong, T., Shen, X., Yates, N.L., et al. (2011). Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502–11519.Search in Google Scholar

Velazquez-Campoy, A., Vega, S., and Freire, E. (2002). Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 41, 8613–8619.Search in Google Scholar

Velazquez-Campoy, A., Vega, S., Fleming, E., Bacha, U., Sayed, Y., and Dirr, H.W. (2003). Protease inhibition in African subtypes of HIV-1. AIDS Rev. 5, 165–171.Search in Google Scholar

Wainberg, M.A. and Brenner, B.G. (2010). Role of HIV subtype diversity in the development of resistance to antiviral drugs. Viruses 2, 2493–2508.Search in Google Scholar

Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B., Phogat, S.K., Poignard, P., and Burton, D.R. (2010). A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028.Search in Google Scholar

Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P., Wang, S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al. (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470.Search in Google Scholar

Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., and Krausslich, H.G. (1998). Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72, 2846–2854.Search in Google Scholar

World Health Organization (WHO) (2013). The use of antiretroviral drugs for treating and preventing HIV infection (Geneva, Switzerland: WHO Press).Search in Google Scholar

Zolopa, A.R., Shafer, R.W., Warford, A., Montoya, J.G., Hsu, P., Katzenstein, D., Merigan, T.C., and Efron, B. (1999). HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131, 813–821.Search in Google Scholar